Katakura M, Koizumi Y, Aizawa T, Takasu N, Yamada T, Yukimura Y, Nagata H
Clin Exp Pharmacol Physiol. 1986 May;13(5):407-15. doi: 10.1111/j.1440-1681.1986.tb00919.x.
One hundred and twenty-one patients with hyperthyroidism of Graves' disease were treated with antithyroid drugs for 3 years and thyroidal response to an increase or decrease of TSH and the serum thyroid stimulating immunoglobulin (TSI) activity were studied in relation to the presence or absence of TSH binding inhibiting immunoglobulin (TBII). TBII activity was positive in 83% of untreated patients but decreased gradually with time during antithyroid drug therapy. Thyroidal radioactive iodine uptake (RAIU) was suppressed by T3 in 86 of 121 treated patients but 16% of suppressible patients had TBII activity. Thyroidal RAIU was not suppressed by T3 in 35 treated patients, and 19 of 35 unsuppressible patients had TBII activity but other 16 patients did not. When suppressible and unsuppressible patients were combined, suppression of serum T4 and thyroidal RAIU by T3 tended to be less in the presence of TBII activity. TSI activity was detected in the sera of untreated patients but did not correlate with TBII activity. TSI activity was undetectable after treatment for 3 years irrespective of presence or absence of TBII activity and T3-suppressibility. TSH, T4 and T3 elevation in response to 500 micrograms thyrotropin releasing hormone (TRH) was normal in all treated patients irrespective of presence or absence of TBII activity and T3-suppressibility. It is suggested that in vivo thyroidal responsiveness to an increase or decrease of endogenous TSH did not correlate with the presence or absence of TBII activity after long-term therapy with antithyroid drugs.
121例格雷夫斯病甲亢患者接受抗甲状腺药物治疗3年,研究了甲状腺对促甲状腺激素(TSH)升高或降低以及血清甲状腺刺激免疫球蛋白(TSI)活性变化的反应,并与促甲状腺激素结合抑制免疫球蛋白(TBII)的有无相关。83%未经治疗的患者TBII活性呈阳性,但在抗甲状腺药物治疗期间,其活性随时间逐渐降低。121例接受治疗的患者中,86例的甲状腺放射性碘摄取(RAIU)被T3抑制,但其中16%可被抑制的患者有TBII活性。35例接受治疗的患者中,甲状腺RAIU未被T3抑制,35例不可被抑制的患者中有19例有TBII活性,另外16例则没有。当可被抑制和不可被抑制的患者合并分析时,存在TBII活性时,T3对血清T4和甲状腺RAIU的抑制作用往往较小。未经治疗的患者血清中可检测到TSI活性,但与TBII活性无关。无论是否存在TBII活性以及T3抑制性,治疗3年后均未检测到TSI活性。无论是否存在TBII活性以及T3抑制性,所有接受治疗的患者对500微克促甲状腺激素释放激素(TRH)的反应中,TSH、T4和T3升高均正常。提示长期使用抗甲状腺药物治疗后,体内甲状腺对内源性TSH升高或降低的反应与TBII活性的有无无关。